Skip To Main Content
Zhongtang Li on Muck Rack

Zhongtang Li

As seen in: Frontiers, MDPI, ACS Publications
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Zhongtang

Contact Zhongtang, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia Click to copy article link Article link copied!

|
By Jiaxu Zhou, Zhongtang Li, Xiaojiao Sun
| ACS Publications
Cite Jump to ExpandCollapse ArticleJune 30, 2026 Design and Synthesis of a Novel Covalent Dihydropteridinone Derivative as a Highly Potent and Orally Bioavailable PLK1 Inhibitor for the Treatment of Chronic Myeloid Leukemia Click to copy article linkArticle link copied! Jiaxu Zhou Jiaxu Zhou State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China Zhongtang Li Zhongtang Li State Key Laboratory of Natural and Biomimetic...
Open in Who Shared Issue with article?

Roxadustat for renal anemia: current clinical experience

|
By Zhongtang Li, Shuping Fang, Zuolin Li, Jialing Ji
| Frontiers
REVIEW article Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1712869 This article is part of the Research TopicCardiorenal Metabolic Health and Diabetic Nephropathy: Mechanisms, Biomarkers, and Therapeutic AdvancesView all articles Introduction Anemia, a condition associated with a high burden of morbidity and adverse clinical outcomes, represents one of the most prevalent complications in patients with chronic kidney disease (CKD) (Hanna et al., 2021).
Open in Who Shared Issue with article?

Discovery of Potent and Selective Blockers Targeting the Epilepsy-Associated KNa1.1 Channel

|
By Zhongtang Li, Qiufeng Wang, Shiqi Liu, Ruqiu Zheng
| dx.doi.org
Journal of Medicinal Chemistry Cite this: J. Med. Chem. 2024, XXXX, XXX Click to copy citationCitation copied! Learn about these metrics Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days. Citations are the number of other articles citing this article, calculated by Crossref and updated daily.
Open in Who Shared View Duplicates (38) Issue with article?
See all 5 articles